VELA Investment Management LLC Increases Stake in Zoetis Inc. $ZTS

VELA Investment Management LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 43.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 22,297 shares of the company’s stock after purchasing an additional 6,769 shares during the period. VELA Investment Management LLC’s holdings in Zoetis were worth $1,602,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Amundi increased its holdings in shares of Zoetis by 26.0% in the second quarter. Amundi now owns 3,988,618 shares of the company’s stock worth $286,622,000 after buying an additional 822,257 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Zoetis during the 2nd quarter worth approximately $5,116,000. California State Teachers Retirement System grew its position in Zoetis by 6,680.3% during the 2nd quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company’s stock worth $3,430,982,000 after acquiring an additional 47,041,186 shares during the last quarter. Guardian Wealth Management Inc. purchased a new position in Zoetis in the 2nd quarter worth approximately $4,608,000. Finally, HB Wealth Management LLC lifted its position in Zoetis by 190.0% in the second quarter. HB Wealth Management LLC now owns 38,820 shares of the company’s stock valued at $2,790,000 after purchasing an additional 25,433 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.1%

Shares of NYSE:ZTS opened at $75.70 on Monday. The firm has a market capitalization of $31.28 billion, a P/E ratio of 12.47, a P/E/G ratio of 1.77 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock has a 50 day moving average price of $75.53 and a 200-day moving average price of $93.61. Zoetis Inc. has a 52-week low of $71.00 and a 52-week high of $155.15.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm’s revenue was down .2% on a year-over-year basis. During the same period in the previous year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Morgan Stanley set a $85.00 price objective on Zoetis in a research note on Friday, August 7th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research report on Tuesday, August 25th. Finally, BNP Paribas Exane decreased their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus target price of $107.43.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.